David Chang

High Impact

Research Physician

UAMS

Also affiliated: General Motors (United States) (1977); University of Iowa (2024); Henry M. Jackson Foundation (2018–2024); Cedars-Sinai Medical Center (2013–2024); Novartis (Switzerland) (2010–2013); Brooke Army Medical Center (2016–2021); Northeastern University (2025); Landstuhl Regional Medical Center (2018); National Institutes of Health (2024); World Vegetable Center (1991); Amgen (United States) (1988–2006); The University of Texas MD Anderson Cancer Center (2000–2009); Johns Hopkins University (2003–2012); National Yang Ming Chiao Tung University (1989–1990); Thomas Jefferson University (2006); The University of Queensland (2008–2014); Queen Mary University of London (1973); University of Novi Sad (2001); University of California, San Francisco (2009); Baylor College of Medicine (2002); University of Colorado Boulder (1968–2005); New York Law School (2010); Hong Kong University of Science and Technology (2019–2020); University of California, Irvine (1997–2001); Johns Hopkins Medicine (2006–2012); Keck Hospital of USC (2002); University of Colorado System (1971–2003); Lismore Base Hospital (2025); Johns Hopkins Bayview Medical Center (2008); University of California San Diego (2013–2015); Massachusetts General Hospital (2016–2020); CT Group Of Institutions (2005); Zhongda Hospital Southeast University (2025); Howard University Hospital (2011); Ligand Pharmaceuticals (United States) (1995); United States Army Institute of Surgical Research (2016); Novartis (Singapore) (2010–2016); American Society of Colon and Rectal Surgeons (2020); University of California San Diego Medical Center (2012); Institute for the Future (2015); BG University Hospital Bergmannsheil Bochum (2002); Cedars-Sinai Smidt Heart Institute (2017–2025); School of Business and Management Novo Mesto (2001); Johns Hopkins Hospital (2005–2010); Office of AIDS Research (2024); October 6 University (2002–2012); Weizmann Institute of Science (1994); The University of Texas Medical Branch at Galveston (2006); Arizona State University (1993–1994); Washington State University (1981–1983); University of Pennsylvania (1997); Joint Base San Antonio (2017); Ruhr University Bochum (2002); Philadelphia University (1997); Walter Reed Army Institute of Research (2015–2024); University of California, Berkeley (1996–2000); American College of Surgeons (2007–2009)

Faculty Researcher

46 h-index 391 pubs 8,955 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 58 institutions in 14 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

David Chang's research interests span multiple disciplines, as evidenced by his diverse publication record. His work includes investigations into stimuli-responsive polymeric nanoplatforms for cancer therapy and biodegradable metal-organic frameworks for tumor microenvironment-targeted synergistic therapy. He has also examined the selective recovery of metals from spent batteries using synergistic roasting processes and the combustion behavior of single iron particles. In the realm of infectious diseases, Chang has contributed to the design and synthesis of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2.

His research also extends to human health studies, including weight gain during dolutegravir transitions within the African Cohort Study, which utilized retrospective analysis. Chang leads a research group and has a notable academic profile, indicated by an h-index of 46 and over 8,900 citations across 391 publications. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Jeannette Y. Lee and Paul M. Darden, as well as Minh Quan Tran from the University of Arkansas at Fayetteville.

Metrics

h-index: 46
Publications: 391
Citations: 8,955

Selected Publications

Retention, blinding, and health outcomes from a rural pediatric obesity feasibility randomized control trial (2026)

DOI OpenAlex
Efforts to Enhance Recruitment and Engagement of Caregivers from Medically Underserved Communities in a Randomized Controlled Trial of a Vaccine Promotion App (2025)

DOI OpenAlex
Corrigendum to “Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children” [Vaccine 61 (2025) 127245] (2025)

DOI OpenAlex
Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children (2025)

DOI OpenAlex
A family-based behavioral group obesity randomized control feasibility trial across a clinical trials network: a focus on contact hours (2025)

4 citations DOI OpenAlex
Validation of remote anthropometric measurements in a rural randomized pediatric clinical trial in primary care settings (2024)

4 citations DOI OpenAlex
Validation of remote anthropometric measurements in a rural randomized pediatric clinical trial in primary care settings (2023)

DOI OpenAlex